Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

Fig. 1

The timeline of the current study and comprehensive genomic classification. A The timeline of ctDNA profiling and objective response evaluation. ctDNA profiling was performed at baseline and after 4 weeks. Objective response was evaluated by mRECIST after 6 weeks of treatment and every two months subsequently. B Comprehensive genomic classification related to HCC included in the Guardant360 panel

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us